Organon & Co. & Samsung Bioepis Co., Ltd. announced that HADLIMA, a biosimilar referencing Humira is now available to patients in the United States. Consistent with Humira, HADLIMA is available in both citrate-free high concentration and citrate-containing low concentration to provide patients with seamless continuity of care. HADLIMA is available at a list price of $1,038, which represents an 85% discount in comparison to the list price of Humira, in order to enable expanded access to patients.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>